Artiva Biotherapeutics (ARTV) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing allogeneic NK cell-based therapies for autoimmune diseases and cancers.

• Lead product, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy evaluated in combination with B-cell targeted mAbs in multiple clinical trials.

• Ongoing trials include Phase 1/1b in SLE/LN, Phase 2a basket trial in refractory autoimmune diseases, and investigator-initiated studies.

• Focused on off-the-shelf, ready-to-ship cell therapies derived from donor cells.

• Shifted resources to autoimmune indications after completing a B-NHL trial in July 2025.

Financial performance and metrics

• As of July 25, 2025, public float was approximately $35.9 million, with 24,425,762 shares outstanding and 9,964,586 held by non-affiliates.

• Last reported sale price of common stock was $3.01 per share on August 4, 2025.

• Net tangible book value as of June 30, 2025, was $6.11 per share; after the offering, as adjusted, $5.65 per share.

Use of proceeds and capital allocation

• Net proceeds intended for working capital and general corporate purposes, including R&D, G&A expenses, and capital expenditures.

• Pending use, proceeds may be invested in short-term, interest-bearing obligations or investment-grade instruments.

• Management retains broad discretion over allocation of proceeds.